# AKBA catalysts: Akebia Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/akba/catalysts

> Akebia Therapeutics, Inc. (AKBA) has 10 upcoming catalysts. The next is the ebribafusp trial start, December 31, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for AKBA?

Akebia Therapeutics, Inc. (AKBA) has 10 upcoming catalysts. The next is the ebribafusp trial start, December 31, 2026. SEC Form 10-Q: "NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS payment upon the earlier of initiation of a Phase 2 clinical trial and December 31, 2026, (iv) will make certain milestone payments upon the achievement of specified commercial milestone events with respect to the net sales of ebribafusp up to an aggregate amount equal to $487.5 million, and (v) will make certain royalty payments based on the net sales of ebribafusp with royalty percentage tiers ranging from the low single digits to mid-teen percentages." [Calendar and source filings](https://sec-api.dev/companies/akba/catalysts)

Source: SEC Form 10-Q, accession 0001517022-26-000051, https://www.sec.gov/Archives/edgar/data/1517022/000151702226000051/akba-20260630.htm (retrieved 2026-11-12). Last confirmed 2026-08-05. Cite: https://sec-api.dev/companies/akba/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Akebia Therapeutics, Inc. |
| Ticker | AKBA (Nasdaq) |
| SEC CIK | 1517022 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/akba |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2022 | [Vafseo® (vadadustat) NDA/BLA submission](https://sec-api.dev/pdufa/vadadustat) | AKBA |  | completed | "For example, we initially submitted a NDA to the FDA for vadadustat in March 2021 and in March 2022 the FDA issued a CRL to our NDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000151702225000046/akba-20250930.htm)) |
| March 29, 2022 | [Vafseo® (vadadustat) complete response letter (CRL)](https://sec-api.dev/pdufa/vadadustat) | AKBA | anemia associated with chronic kidney disease, or CKD | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22215192_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| May 2022 | [Akebia Therapeutics, Inc. complete response letter (CRL)](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed, complete response letter | "Specifically, following receipt of the CRL, we implemented a reduction of our workforce in April and May 2022 by approximately 42% across all areas of our Company (47% inclusive of the closing of the majority of open positions), including several members of management." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000151702225000046/akba-20250930.htm)) |
| March 27, 2024 | [Vafseo® (vadadustat) NDA/BLA submission](https://sec-api.dev/pdufa/vadadustat) | AKBA |  | completed | "As a result, we filed the FDRR and, following the FDRR, we filed a resubmission to our NDA, and the FDA approved Vafseo on March 27, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000084/akba-20260930.htm)) |
| March 27, 2024 | [Vafseo® (vadadustat) FDA approval](https://sec-api.dev/pdufa/vadadustat) | AKBA | To treat anemia due to chronic kidney disease | completed, approved | "Vafseo \| vadadustat \| 3/27/2024 \| To treat anemia due to chronic kidney diseaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| June 30, 2024 | [Vafseo® (vadadustat) FDA approval](https://sec-api.dev/pdufa/vadadustat) | AKBA |  | completed, approved | "The Term Loan Facility had an initial maturity date of March 31, 2025, which was automatically extended to January 29, 2028, or the Maturity Date, since we received FDA approval for Vafseo prior to June 30, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1517022/000162828025012470/akba-20241231.htm)) |
| March 13, 2025 | [Vafseo® (vadadustat) earnings report](https://sec-api.dev/pdufa/vadadustat) | AKBA |  | completed | "Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702225000017/drafpr12312024.htm)) |
| March 31, 2025 | [Vafseo® (vadadustat) FDA approval](https://sec-api.dev/pdufa/vadadustat) | AKBA |  | completed, approved | "The Term Loan Facility had an initial maturity date of March 31, 2025, which was automatically extended to January 29, 2028, after the Company received FDA approval for Vafseo, or the BlackRock Maturity Date." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000084/akba-20260930.htm)) |
| May 8, 2025 | [Akebia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed | "Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702225000027/q12025pr1.htm)) |
| July 15, 2025 | [Akebia Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000039/akba-20260331.htm)) |
| August 7, 2025 | [Akebia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed | "Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702225000034/q22025pr.htm)) |
| late 2025 | [Vafseo® (vadadustat) trial start](https://sec-api.dev/pdufa/vadadustat) | AKBA |  | scheduled | "For example, we plan to start a Phase 3 trial in the second half of 2025 to potentially expand Vafseo label to include the treatment of late-stage NDD-CKD patients; however, the FDA may not agree with our study design or we may not successfully demonstrate safety and/or efficacy needed to obtain regulatory approval or we may be unable to successfully complete the trial when anticipated, or at all." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000162828025023460/akba-20250331.htm)) |
| November 10, 2025 | [Akebia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed | "Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702225000045/q32025pr1.htm)) |
| 1H 2026 | [AKB-9090 trial start](https://sec-api.dev/pdufa/akb-9090) | AKBA | cardiac surgery-related acute kidney injury, or CS-AKI | scheduled | "We plan to initially evaluate AKB-9090 for the treatment of cardiac surgery-related acute kidney injury, or CS-AKI, and we expect to initiate a Phase 1 study in healthy volunteers in the first half of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/akba-20251231.htm)) |
| January 6, 2026 | [Praliciguat trial start](https://sec-api.dev/pdufa/praliciguat) | AKBA | biopsy-confirmed FSGS, a rare kidney disease, and dosed the first patient in December 2025 | completed | "Although we performed additional work to manufacture product for clinical trials than originally anticipated before we could initiate the trial for praliciguat, on January 6, 2026, we announced that the first patient was dosed in a Phase 2 clinical trial in the U.S. However, even though the clinical trial has started, we may be unsuccessful in developing praliciguat." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000051/akba-20260630.htm)) |
| February 26, 2026 | [Akebia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed | "Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000019/drafpr12312025.htm)) |
| Apr 2026 | [AKB-9090 trial start](https://sec-api.dev/pdufa/akb-9090) | AKBA |  | completed | "•In April 2026, Akebia initiated a Phase 1 study of AKB-9090 in up to 70 healthy volunteers with topline data expected in early 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000038/q12026pr.htm)) |
| May 7, 2026 | [Akebia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed | "Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000038/q12026pr.htm)) |
| August 5, 2026 | [Akebia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed | "Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000050/q22026pr.htm)) |
| August 5, 2026 | [Ebribafusp trial start](https://sec-api.dev/pdufa/ebribafusp) | AKBA |  | completed | "•In August, Akebia announced that it initiated a Phase 2 open-label basket trial of ebribafusp (previously known as AKB-097 and ADX-097), a next-generation complement inhibitor." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000050/q22026pr.htm)) |
| August 12, 2026 | [Vafseo® (vadadustat) primary completion](https://sec-api.dev/pdufa/vadadustat) | AKBA | Anemia of Chronic Kidney Disease | completed | "NCT06901505 (To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Akebia Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06901505)) |
| late 2026 | [AKB-9090 topline data readout](https://sec-api.dev/pdufa/akb-9090) | AKBA |  | scheduled | "The study is expected to begin in the first half of 2026 with topline data expected by the end of the year." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000019/drafpr12312025.htm)) |
| Q4 2026 | [Vafseo® (vadadustat) topline data readout](https://sec-api.dev/pdufa/vadadustat) | AKBA | Anemia of Chronic Kidney Disease | scheduled | "•In July, enrolled the first patient in VOCAL, a Phase IIIb trial evaluating three times weekly (TIW) dosing of Vafseo versus ESAs, which is expected to report topline data in Q4 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000019/drafpr12312025.htm)) |
| November 5, 2026 | [Akebia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed | "Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000083/q32026pr.htm)) |
| November 5, 2026 | [Ebribafusp alfa trial start](https://sec-api.dev/pdufa/ebribafusp-alfa) | AKBA |  | completed | "•In September, Akebia announced it had dosed the first patient in a Phase 2 open-label basket trial of ebribafusp alfa, which Akebia believes has the potential to be a next-generation complement inhibitor." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000083/q32026pr.htm)) |
| December 31, 2026 | [Ebribafusp trial start](https://sec-api.dev/pdufa/ebribafusp) | AKBA | three rare glomerular kidney diseases, with initial data | scheduled | "NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS payment upon the earlier of initiation of a Phase 2 clinical trial and December 31, 2026, (iv) will make certain milestone payments upon the achievement of specified commercial milestone events with respect to the net sales of ebribafusp up to an aggregate amount equal to $487.5 million, and (v) will make certain royalty payments based on the net sales of ebribafusp with royalty percentage tiers ranging from the low single digits to mid-teen percentages." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000051/akba-20260630.htm)) |
| 2027 | [Ebribafusp interim data readout](https://sec-api.dev/pdufa/ebribafusp) | AKBA | three rare glomerular kidney diseases, with initial data | scheduled | "Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; initial data expected in 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000050/q22026pr.htm)) |
| 2027 | [Ebribafusp alfa interim data readout](https://sec-api.dev/pdufa/ebribafusp-alfa) | AKBA |  | scheduled | "First patient dosed in Phase 2 open-label basket trial evaluating ebribafusp alfa in multiple rare kidney diseases; initial data expected in 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000083/q32026pr.htm)) |
| early 2027 | [Vafseo® (vadadustat) topline data readout](https://sec-api.dev/pdufa/vadadustat) | AKBA | anemia due to CKD in dialysis | scheduled | "VOICE topline results are expected in early 2027 with the potential to help establish Vafseo as a standard of care to treat anemia due to CKD in dialysis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000003/akba_2026corporatereleasex.htm)) |
| early 2027 | [Akebia Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | scheduled | "VOICE topline results are expected in early 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000019/drafpr12312025.htm)) |
| early 2027 | [AKB-9090 topline data readout](https://sec-api.dev/pdufa/akb-9090) | AKBA |  | scheduled | "•In April 2026, Akebia initiated a Phase 1 study of AKB-9090 in up to 70 healthy volunteers with topline data expected in early 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000038/q12026pr.htm)) |
| June 2027 | [Praliciguat (part a) primary completion](https://sec-api.dev/pdufa/praliciguat-part-a) | AKBA | Focal Segmental Glomerulosclerosis | scheduled | "NCT07268638 (A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Akebia Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07268638)) |
| Jun to Sep 2027 | [Praliciguat (part a) topline data readout](https://sec-api.dev/pdufa/praliciguat-part-a) | AKBA | Focal Segmental Glomerulosclerosis | scheduled | "NCT07268638 (A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Akebia Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07268638)) |
| February 2028 | [ADX-097 primary completion](https://sec-api.dev/pdufa/adx-097) | AKBA | IgA Nephropathy; Lupus Nephritis (LN); C3 (Complement Component 3) Glomerulopathy | scheduled | "NCT06419205 (A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Akebia Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06419205)) |
| Feb to May 2028 | [ADX-097 topline data readout](https://sec-api.dev/pdufa/adx-097) | AKBA | IgA Nephropathy; Lupus Nephritis (LN); C3 (Complement Component 3) Glomerulopathy | scheduled | "NCT06419205 (A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Akebia Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06419205)) |

## Drugs

- [ADX-097](https://sec-api.dev/pdufa/adx-097): IgA Nephropathy
- [AKB-9090](https://sec-api.dev/pdufa/akb-9090): cardiac surgery-related acute kidney injury, or cs-aki
- [Ebribafusp](https://sec-api.dev/pdufa/ebribafusp): three rare glomerular kidney diseases, with initial data
- [Ebribafusp alfa](https://sec-api.dev/pdufa/ebribafusp-alfa): 
- [Praliciguat](https://sec-api.dev/pdufa/praliciguat): biopsy-confirmed fsgs, biopsy-confirmed fsgs, a rare kidney disease, and dosed the first patient in december 2025
- [Praliciguat (part a)](https://sec-api.dev/pdufa/praliciguat-part-a): Focal Segmental Glomerulosclerosis
- [Vafseo® (vadadustat)](https://sec-api.dev/pdufa/vadadustat): anemia due to ckd in adults, anemia associated with chronic kidney disease, or ckd, anemia due to ckd, anemia due to chronic kidney disease in adults, anemia due to ckd in dialysis, To treat anemia due to chronic kidney disease, Anemia of Chronic Kidney Disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/akba/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AKBA catalysts: Akebia Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/akba/catalysts

```bibtex
@misc{secapidev_companies_akba_catalysts_20261116,
  title        = {AKBA catalysts: Akebia Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/akba/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_akba_catalysts_20261116","title":"AKBA catalysts: Akebia Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/akba/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
